![](/images/graphics-bg.png)
Clinical outcome of invasive pituitary prolactinomas treated with cabergoline
المؤلف
المصدر
al-Kindy College Medical Journal
العدد
المجلد 15، العدد 2 (31 ديسمبر/كانون الأول 2019)، ص ص. 50-57، 8ص.
الناشر
تاريخ النشر
2019-12-31
دولة النشر
العراق
عدد الصفحات
8
التخصصات الرئيسية
الموضوعات
الملخص EN
Background: Treatment of invasive prolactinoma, which has several characteristics including invasive growth into cavernous sinuses and formation of giant adenomas compressing adjacent neural structures, resulting in neurological dysfunction, has been very challenging.
There are relatively few reports available describing long-term treatment outcome.
Aims of the study: In this study we evaluate the results of cabergoline administration as initial treatment during 4 years follow up period.
Methods: We prospectively categorized 36 patients into four groups according to the results of 3 months of cabergoline treatment: group 1, tumor volume reduction (TVR) ˃25% with normalized serum prolactin (NP) (n = 24); group 2, TVR˃25% without NP (n = 4); group 3, TVR ˂25% with NP (n = 5); and group 4, TVR ˂25% without NP (n = 3).
Results: During follow-up, 22 patients (91.7%) in group 1 achieved TVR˃50% with NP.
Three patients (75%) in group 2 achieved TVR˃50% with NP after treatment for 8 months.
In group 3, four patients (80.0%) continued medication because of improvement of symptoms and achieved additional TVR(18.8–46.4%).
Surgery was performed on five patients (one in group 2, one in group 3, and three in group 4), and complete resection was achieved in four (80.0%).
Overall, 25 (69.4%) of the 36 patients treated with cabergoline had complete response and 6 (16.7%) had partial response but did not require surgery.
Thus, the overall response rate was 86%,with only five patients (14%) requiring surgical debulking.
NP was not achieved by surgery alone in all cases, even after total resection of tumor.
Conclusion: Patients who achieve TVR˃25%with NP with 3 months of cabergoline administration had a high possibility of showing good long term response (TVR˃50% with NP) to cabergoline.
A higher dose of dopamine agonist (DA) should be considered for patients who achieve TVR˃25% without NP.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Arkawazi, Basam M. Flamerz. 2019. Clinical outcome of invasive pituitary prolactinomas treated with cabergoline. al-Kindy College Medical Journal،Vol. 15, no. 2, pp.50-57.
https://search.emarefa.net/detail/BIM-945806
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Arkawazi, Basam M. Flamerz. Clinical outcome of invasive pituitary prolactinomas treated with cabergoline. al-Kindy College Medical Journal Vol. 15, no. 2 (2019), pp.50-57.
https://search.emarefa.net/detail/BIM-945806
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Arkawazi, Basam M. Flamerz. Clinical outcome of invasive pituitary prolactinomas treated with cabergoline. al-Kindy College Medical Journal. 2019. Vol. 15, no. 2, pp.50-57.
https://search.emarefa.net/detail/BIM-945806
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 56-57
رقم السجل
BIM-945806
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)